GSE148697

Identification of Lead Drug Candidates for COVID-19 based on Drug Screening Using Human Pluripotent Stem Cell-Derived Cells/Organoids

Submitted by David Redmond (Weill Cornell Medicine, USA) on Apr 15 2020

Platform: ngs – Illumina NovaSeq 6000 (Homo sapiens)

Pubmed: None listed

Summary We systematically probed which cell types are permissive to SARS-CoV-2 infection. Transcriptomic analysis following SARS-CoV-2 infection of hPSC-derived lung organoids revealed upregulation of chemokines but not type I/III interferon signaling, similar to what was seen in primary human COVID-19 pulmonary infection.

6 Samples

ID	Title	Cell Type	Timepoint	Reported Virus	Virus Species
GSM4476798	Infected cells from lung for the study of SAR-CoV-2, 1	lung	24 hrs	sars-Cov2	Severe acute respiratory syndrome-related coronavirus
GSM4476799	Infected cells from lung for the study of SAR-CoV-2, 2	lung	24 hrs	sars-Cov2	Severe acute respiratory syndrome-related coronavirus
GSM4476800	Infected cells from lung for the study of SAR-CoV-2, 3	lung	24 hrs	sars-Cov2	Severe acute respiratory syndrome-related coronavirus
GSM4476801	Mock-infected lung, 1	lung		Mock	Uninfected
GSM4476802	Mock-infected lung, 2	lung		Mock	Uninfected
GSM4476803	Mock-infected lung, 3	lung		Mock	Uninfected